<ul data-eligibleForWebStory="false"><li>Glenmark Pharmaceuticals Ltd. struck a deal with AbbVie for its cancer drug ISB 2001, receiving mixed reactions from brokerages.</li><li>Nuvama maintained a 'neutral' outlook, while HSBC and Axis Capital are more optimistic about the deal's transformative impact and growth prospects for Glenmark.</li><li>The deal includes an upfront payment of $700 million, potential milestone payments of up to $1.225 billion, and tiered royalties on sales, providing a significant financial boost.</li><li>HSBC raised its target price to Rs 2,275, emphasizing the transformative nature of the deal and the potential for better sales growth and profitability for Glenmark.</li></ul>

Glenmark Pharma's Mega Deal With AbbVie Has Brokerages Mixed

Discover more